DRUG/DEVICE

Treprostinil inhalation solution

ROUTE OF ADMINISTRATION

Inhaled

THERAPEUTIC PLATFORM

Tyvaso®

CLINICAL TRIAL

TERRITORY

Worldwide

COMMERCIAL PRODUCT

www.tyvaso.com

STATUS

Phase 3

(All endpoints met;
FDA label supplement accepted for review; April 2021 PDUFA date)

Tyvaso® for PH WHO Group 3 is investigational and not FDA approved.